Incorrect use of acetaminophen that results in severe liver injury is among the most common adverse drug events (ADEs) in the United States of America (USA), and other countries around the world. Compared to any other drug, it is also on the top for emergency calls, emergency room visits, and acute liver failure in the USA. Consequently, regulating acetaminophen has become a heated and unresolved public debate. During the last decades, multiple efforts have taken place to address the issue, mostly focused on the premise that inappropriate labeling is a leading cause of such ADEs, for failure in communicating the associated risks through warnings. Unlike previous studies, this paper illustrates the importance of considering human factors principles. Three different warning labels were designed and evaluated. The results showed no statistically significant effect, despite the application of best practices for label warning design. Non-design factors, the warning process and why a warning could fail are also illustrated. Implications could help researchers, policy makers, and manufacturers to consider focusing less on traditional labeling interventions, and to invest efforts more systematically considering also the current trends and the current needs of consumers.
Get full access to this article
View all access options for this article.
References
1.
BaciuA.StrattonK.BurkeS. (2007). The future of drug safety: promoting and protecting the health of the public. Health (San Francisco).
2.
BenninF.RotherH. A. (2015). “But it’s just paracetamol”: Caregivers’ ability to administer over-the-counter painkillers to children with the information provided. Patient Education and Counseling, 98(3), 331–337.
3.
CasselC. K.SaundersR. S. (2014). Engineering a Better Health Care System: A Report From the President’s Council of Advisors on Science and Technology. JAMA, 312(8), 787–788.
4.
CatlinJ. R.PechmannC. C.BrassE. P. (2015). Dangerous Double Dosing : How Naive Beliefs Can Contribute to Unintentional Overdose with Over-the-Counter Drugs, 34(2), 194–209.
5.
CDER. (2015). Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use — Labeling for Products That Contain Acetaminophen Guidance for Industry, (November).
6.
Dale ComptonW.GanjiangG.ReidP. P.GrossmanJ. H. (2005). Building a Better Delivery System: A New Engineering/Health Care Partnership. Building.
7.
DartR. C.GreenJ. L. (2016). The prescription paradox of acetaminophen safety. Pharmacoepidemiology and Drug Safety, 25(5), 599–601.
8.
DeJoyD. M.WogalterM. S. (1993). Warnings and risk communication. Safety Science.
FDA. (2011). FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. Retrieved July2, 2017, from http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm
12.
FrantzJ. P.YoungS. L.RhoadesT. P.WisniewskiE. C. (2005). Predicted versus Actual Response to Warning Signs and Labels: Examining the Role of ANSI Z535 Features. Proceedings of the Human Factors and Ergonomics Society Annual Meeting, 49(19), 1785–1789.
GodfreyS. S.LaugheryK. R. (1984). The Biasing Effects of Product Familiarity on Consumers’ Awareness of Hazard. Proceedings of the Human Factors and Ergonomics Society Annual Meeting, 28(5), 483–486.
15.
GoyalR. K.RajanS. S.EssienE. J. (2012). Effectiveness of FDA’s new over-the-counter acetaminophen warning label in improving consumer risk perception of liver damage. Journal of Clinical Pharmacy and Therapeutics, 37(6), 681–685.
16.
HellierE.EdworthyJ.DerbyshireN.CostelloA. (2006). Considering the impact of medicine label design characteristics on patient safety. Ergonomics, 49(5–6), 617–630.
17.
Institute of Medicine (IOM). (2008). Standardizing Medication Labels: Confusing Patients Less, Workshop Summary. Board on Population Health and Public Health Practice. National Academies Press.
18.
KingJ. P.DavisT. C.BaileyS. C.JacobsonK. L.HedlundL. A.Di FrancescoL.. . . WolfM. S. (2011). Developing consumer-centered, nonprescription drug labeling: A study in acetaminophen. American Journal of Preventive Medicine, 40(6), 593–598.
19.
KingJ. P.McCarthyD. M.SerperM.JacobsonK. L.MullenR. J.ParkerR. M.WolfM. S. (2015). Variability in Acetaminophen Labeling Practices: a Missed Opportunity to Enhance Patient Safety. Journal of Medical Toxicology, 11(4), 410–414.
20.
KrenzelokE. P. (2009). The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member. Clinical Toxicology, 47(8), 784–789.
21.
KrenzelokE. P.RoyalM. A. (2012). Confusion: Acetaminophen dosing changes based on NO evidence in adults. Drugs in R and D.
22.
LaugheryK. R.WogalterM. S. (2006). Designing Effective Warnings. Reviews of Human Factors and Ergonomics, 2(1), 241–271.
MajorJ. M.ZhouE. H.WongH. L.TrinidadJ. P.PhamT. M.MehtaH.. . . WillyM. E. (2015). Trends in rates of acetaminophen-related adverse events in the United States. Pharmacoepidemiology and Drug Safety.
25.
McDonaldD. D.AmendolaM. G.InterlandiE.WallK.LewchikB.PolouseL.. . . LingL. (2007). Effect of reading additional safety information on planned use of over-the-counter analgesics. Public Health Nursing, 24(3), 230–238.
ReasonJ. (1990). Human error. Human error. Cambridge University Press.
28.
RogersW. A.LamsonN.RousseauG. K. (2000). Warning research: an integrative perspective. Human Factors, 42(1), 102–39.
29.
SandersM. S.McCormickE. J. (1993). Human Error, Accidents, and Safety. In Human Factors in Engineering and Design. (pp. 655–695).
30.
SawantR. V.GoyalR. K.RajanS. S.PatelH. K.EssienE. J.SansgiryS. S. (2016). Factors associated with intention to engage in self-protective behavior: The case of over-the-counter acetaminophen products. Research in Social and Administrative Pharmacy, 12(2), 327–335.
31.
ShaverE. F.BraunC. C. (2000). Effects of Warning Symbol Explicitness and Warning Color on Behavioral Compliance. Proceedings of the Human Factors and Ergonomics Society Annual Meeting, 44(27), 290–293.
32.
ShaverE. F.YoungS. L.FrantzJ. P.RhoadesT. P.HallS. M.ShahR. J. (2006). Comparison of ANSI and ISO Standard Formats on People’s Response to Product Warnings. Proceedings of the Human Factors and Ergonomics Society 50th Annual Meeting, 50, 2197–2201.
33.
ShiffmanS.CottonH.JessurunC.SembowerM.PypeS.PhillipsJ. (2016). Testing of Candidate Icons to Identify Acetaminophen-Containing Medicines. Pharmacy, 4(1), 10.
34.
SollerR. W.HoT.LightwoodJ. M. (2015). Improved Label and Liver Warning for Nonprescription Acetaminophen Products. Therapeutic Innovation & Regulatory Science, 49(6), 890–897.
35.
TrivediH.TrivediA.HannanM. F. (2014). Readability and comprehensibility of over-the-counter medication labels. Renal Failure, 6049(3), 1–5.
36.
WogalterM. S. (2006). Purposes and Scope of Warnings. In Handbook of Warnings (pp. 3–9). CRC Press.
37.
WogalterM. S.ConzolaV. C.Smith-JacksonT. L. (2002). Research-based guidelines for warning design and evaluation. Applied Ergonomics, 33(3), 219–230.
38.
YoonE.BabarA.ChoudharyM.KutnerM.PyrsopoulosN. (2016). Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. Journal of Clinical and Translational Hepatology, 4(2), 131–42.
